Activation-induced cytidine deaminase (AID), the only enzyme that is known to be able to induce mutations in the human genome, is required for somatic hypermutation and class-switch recombination in B lymphocytes. Recently, we showed that AID is implicated in the pathogenesis of human cancers including hepatitis C virus (HCV)-induced human hepatocellular carcinoma (HCC). In this study, we established a new AID transgenic mouse model (TNAP-AID) in which AID is expressed in cells producing tissue-nonspecific alkaline phosphatase (TNAP), which is a marker of primordial germ cells and immature stem cells, including ES cells. High expression of TNAP was found in the liver of the embryos and adults of TNAP-AID mice. HCC developed in 27% of these mice at the age of approximately 90 weeks. The HCC that developed in TNAP-AID mice expressed a-fetoprotein and had deleterious mutations in the tumour suppressor gene Trp53, some of which corresponded to those found in human cancer. In conclusion, TNAP-AID is a mouse model that spontaneously develops HCC, sharing genetic and phenotypic features with human HCC, which develops in the inflamed liver as a result of the accumulation of genetic changes.
Introduction
It is widely recognized that mutations of oncogenes, tumour suppressor genes and genomic stability genes play pivotal roles in cancer development (Vogelstein and Kinzler, 2004) . Despite remarkable progress in our knowledge of the molecular mechanisms of individual cancer-related genes, surprisingly little is known about the fundamental aspects of when and how mutations are introduced into what kind of cell populations (for example, differentiated cells versus tissue stem cells).
To address this problem, a new mechanism of mutagenesis for cancer development has recently been proposed (Kinoshita and Nonaka, 2006; Marusawa, 2008) . It hypothesizes that at least some cancer-related mutations are introduced by activation-induced cytidine deaminase (AID), an enzyme that is expressed in activated B lymphocytes, and is required for somatic hypermutation (SHM) and class-switch recombination of antibody genes (Honjo et al., 2002) . The hypothesis is based on the following observations: (1) AID can induce mutations in non-B cells (Yoshikawa et al., 2002) ; (2) AID transgenic mice develop various tumours, including T-cell lymphoma and lung microadenoma (Okazaki et al., 2003) and (3) AID can be induced in human hepatic, gastric and biliary epithelial cells when stimulated with pro-inflammatory cytokines, such as transforming growth factor-b and tumor necrosis factor-a, and when challenged with pathogens, such as hepatitis C virus (HCV) and Helicobacter pylori. AID is detected in the liver, stomach and bile duct in humans (Kou et al., 2006; Endo et al., 2007; Matsumoto et al., 2007; Komori et al., 2008) . On the basis of this evidence, AID is a potential candidate for a mutagen in human cancers.
To substantiate this hypothesis, there is an urgent need for the establishment of an AID transgenic mouse model that recapitulates the development of human cancer. However, we have found earlier that it is difficult to analyse epithelial tumours of tissues other than lymphoid malignancies in a transgenic mouse model with constitutive and ubiquitous AID expression because of early death of the mice from lethal T-cell lymphoma (Okazaki et al., 2003) .
We generated earlier AID transgenic mice that can express AID conditionally in a Cre-recombianasedependent manner (AID conditional transgenic, AID cTg) and reported B-cell-specific AID transgenic mice obtained by crossing AID cTg mice with B-cell-specific Cre transgenic mice (Muto et al., 2006) . In this study, we used a different Cre transgenic mouse line that expresses Cre in cells producing tissue nonspecific alkaline phosphatase (TNAP), as the mating partner of AID cTg mice.
TNAP is a member of the alkaline phosphatase family encoded by the Akp2 gene and alternatively designated alkaline phosphatase 2, liver. As TNAP is also known as a marker of primordial germ cells and immature stem cells, including ES cells (Urven et al., 1993; Kues et al., 2005; Wang et al., 2005) , we initially speculated that AID expression in TNAP-positive cells might contribute to the development of tumours of germ cell origin. However, the resulting mice frequently developed hepatocellular carcinoma (HCC) but not germ cell tumours or lethal lymphomas. Histological and molecular analyses of HCC revealed genetic and phenotypic similarities to human tumours, including deleterious mutations in the p53 gene and the expression of a-fetoprotein, a well-known marker of human HCC. This mouse model should be useful for studies on the prevention and treatment of hepatic cancer, which is a major health concern worldwide.
Results
We crossed AID cTg mice with TNAP-Cre mice (Lomeli et al., 2000; Figures 1a and b) . AID cTg mice possess a CAG promoter-driven AID transgene, whose expression is blocked by insertion of the gene encoding enhanced green fluorescent protein (hereafter GFP) flanked by two loxP sites (Figure 1a) . Therefore, the expression of Cre recombinase removes GFP and induces AID expression (Muto et al., 2006) . TNAPCre mice were generated by inserting the coding sequence of Cre recombinase into the Akp2 locus of the 129/Sv mouse genome, and Cre was expressed in primordial germ cells in the embryonic genital ridge region (Lomeli et al., 2000) . We crossed homozygous female AID cTg mice on a C57BL/6 background with heterozygous male TNAP-Cre mice to obtain doubletransgenic mice (TNAP-AID) and their littermate control AID cTg mice. Non-transgenic (wild-type, WT) and TNAP-Cre control mice on a C57BL/6:129/ Sv hybrid background were obtained by mating female C57BL/6 mice with heterozygous male TNAP-Cre mice (Figure 1b) . Accordingly, a total of 101 mice were prepared, which included 28 TNAP-AID, 29 AID cTg, 16 TNAP and 28 WT mice.
Most mice were viable at 90 weeks (Figure 1c ), whereas in our earlier study, most AID transgenic mice died because of the lethal lymphoid malignancies, majority of which died within 50 weeks (Okazaki et al., 2003) . Although TNAP is expressed in primordial germ cells, we did not observe any incidence of testicular or ovarian tumours in TNAP-AID mice. Instead of germ cell tumours, we frequently observed macroscopic liver tumours in TNAP-AID mice. Table 1 summarizes the frequency and spectrum of tumours that developed in TNAP-AID and control mice. Interestingly, liver tumours were observed in TNAP-AID mice but not in the control groups; the difference between TNAP-AID and AID cTg mice (P ¼ 0.017) and that between TNAP-AID and WT mice (P ¼ 0.018) was significant. There were no differences among the groups with regard to weights of body, liver, spleen and kidneys in healthy mice (data not shown).
Macroscopically, multiple liver nodules were frequently observed in mice with liver tumour (4 out of 15; Table 1, Figure 2a) . The number and size of the nodules varied. Microscopically, liver tumours showed various degrees of cellular atypia, from adenoma to HCC with occasional 'carcinoma in adenoma', suggesting ongoing progression. The expression of a-fetoprotein, a marker of human HCC, was detected in the tumours by immunohistochemical analyses (Figure 2b ) and quantitative reverse transcription PCR (qRT-PCR) (Supplementary Figure 1) . None of the tumours showed Sequences of some tumour suppressor genes and oncogenes in the tumours were determined. Significant numbers of mutations were observed in the Trp53 gene encoding the p53 protein ( Table 2 ). The non-transcribed region upstream of the promoter did not contain mutations, an observation that is consistent with the transcription dependence of mutagenesis by AID (Yoshikawa et al., 2002) . Majority of mutations were single-base substitutions with significant GC bias, another footprint of AID (Figure 3a ) (Yoshikawa et al., 2002) . There was no significant correlation between the distribution of mutations and those of SHM hot spot motifs (RGYW/WRCY) and DNA secondary structures (Supplementary Figure 2) . Interestingly, the mutation frequency was the highest in cancer tissues followed by non-cancerous TNAP-AID liver and lowest in normal liver of WT mice, which corresponds to the PCR error rate or the background rate in this assay. The increase in mutation frequency in HCC compared with non-cancerous liver was because of the increase in single-base insertion events mostly at the homonucleotide tracts, leading to frameshift mutations in the 5 0 -half of the coding region (Table 2 and Figure 3b ). Most of TNAP-AID liver mutations occurred in the DNA-binding domain of p53, which is critical for its function (Table 3) .
Although small volumes (approximately 50 mm 3 ) of normal and cancerous liver tissues were dissected for mutation analysis, the identified mutations were quite diverse, suggesting that the sampled tissue block contained multiple HCC nodules, each representing monoclonal expansion. Such heterogeneity was verified by two independent series of PCR, plasmid cloning and sequencing for the same sample: there were few overlaps of mutations. For example, 8 and 7 clones derived from HCC of mouse TA113 contained nonsynonymous point mutations out of sequenced 27 and 40 clones in the first and second experiment, respectively. The mutation patterns were completely different except C808G (R270G), which appeared thrice and once in the first and the second trial, respectively. Table 3 lists the combined results of the two experiments. The most frequent mutations were C790T(R264W) and C808G(R270G), the latter corresponding to one of the second most important mutational targets (R273) in human cancers (Figure 3b, top) . Despite extensive sequencing, no mutations were found in Myc, Pten and Cdkn2a (p16 and p19
Arf ) genes (Supplementary Figure 3) . The Trp53 mutation frequency in the thymus was significantly lower than in the liver of TNAP-AID mice, which is consistent with the lack of lethal T-cell lymphomagenesis (Table 2) .
To determine why liver tumours developed, TNAP expression in various organs was examined by qRT-PCR in E14.5 embryos and 53-to 74-week-old adult mice of strain C57BL/6. TNAP was ubiquitously expressed at a relatively high level in the liver and intestine of the embryos and in the liver and testis of the adults (Figure 4a ). In agreement with this wide distribution of TNAP expression, GFP expression in TNAP-AID mice was absent in most organs in adults ( Figure 4c ). The substantial levels of AID expression were confirmed by qRT-PCR ( Figure 4b ) and western blotting ( Figure 4d ) in various organs of the adult TNAP-AID mice but not of AID cTg mice. The presence of AID protein and loss of GFP were detected in the non-cancerous liver sections of TNAP-AID mice ( Figure 5 ). Taken together, these findings suggest that constitutive AID expression in hepatic lineage, including fetal and adult liver, contributes to the high incidence of liver tumours.
As reported for AID transgenic mice with the ubiquitous promoter, lymphomas were observed in TNAP-AID mice (Table 1) . Although the frequency of lymphomas in the TNAP-AID group was higher than those in the other groups, the differences between TNAP-AID and AID cTg mice (P ¼ 0.508) and those between TNAP-AID and WT mice (P ¼ 0.150) were not statistically significant. The survival curve analysis (Figure 1c) suggested that there was no significant difference between the TNAP-AID and TNAP-Cre groups (P ¼ 0.515), indicating that the lymphomas in TNAP-AID mice were less aggressive than those in the transgenic mice with ubiquitous AID expression. Histologically, the lymphomas in TNAP-AID mice exhibited nodular appearance, which was different from that of the diffusely infiltrating lymphoma that develops in the ubiquitous promoter-driven AID transgenic mice (data not shown). This difference suggests that different mechanisms underlie tumorigenesis of lymphoid cells between these mice. We confirmed that GFP expression and Cre-mediated excision of GFP occurred efficiently in CD3-positive T cells of AID cTg and TNAP-AID mice, respectively (Supplementary Figure 4) . This suggests that AID is expressed in T cells of TNAP-AID mice. Hepatic cancer by AID in mice Hepatic cancer by AID in mice A Takai et al Macroscopic tumours of other organs included one case of lung adenocarcinoma and one case of gastric cancer (squamous cell carcinoma) (Table 1 and Figure 2c) . These rare tumours were restricted to the TNAP-AID group and likely to be caused by AID expression. However, the small number of tumours precludes a quantitative discussion on causal relationships, except for liver tumours. Sequencing analysis revealed that Trp53 mutation frequency in gastric cancer tissue was 2.32/10 4 , a comparable level to that observed in HCC tissues (Tables 2 and 3 as well as Figure 3 ). Unfortunately, we could not carry out mutation analyses on the lung cancer tissue because of its small size. We did not examine microscopic tumours except for subpleural lung microadenomas, which were observed in the TNAP-AID mice, a finding similar to that in the AID transgenic mice in our earlier study (Okazaki et al., 2003) . In addition, two cases of gastric adenocarcinoma were found incidentally by microscopic examination (Figure 2c ), suggesting that many microscopic tumours may have been overlooked.
Discussion
Here we describe TNAP-AID mice as a novel model of hepatocarcinogenesis, which occurs as a result of the accumulation of mutations in chronically inflamed liver in humans, often caused by infection with hepatitis viruses. The TNAP-AID mouse model exhibits several characteristics of human HCC, in that the mice develop HCC spontaneously and the HCC tissue expresses a-fetoprotein and that it has the p53 gene mutations, some of which cause the same amino acid replacements as those seen in human tumours. Earlier HCC mouse models include mice with genetic modifications of Lkb1, Mdr2, Aox and Pten genes (Fan et al., 1998; Nakau et al., 2002; Horie et al., 2004; Katzenellenbogen et al., 2006) , transgenic mice overexpressing c-myc, transforming growth factor-a, transforming growth factor-b1, HBx of hepatitis B virus and HCV core (Sandgren et al., 1989; Kim et al., 1991; Murakami et al., 1993; Koike et al., 1994 Koike et al., , 2002 Factor et al., 1997; Riehle et al., 2008) and chemical-or diet-induced HCC (Sell, 2001; Maeda et al., 2005; Ma et al., 2006; Sakurai et al., 2006) . In contrast to these models, our TNAP-AID model is unique because it does not arbitrarily target specific oncogenes, tumour suppressors or stability genes. In addition, it does not use chemical mutagens or specific dietary conditions that are not associated with human HCC. The development of Trp53 mutations is another feature of this model because it is unprecedented in any earlier mouse HCC models as mentioned above.
Liver tumours were occasionally observed in our earlier AID transgenic mice . However, it was difficult to use these mice as a liver tumour model because of early death from lethal lymphomas. Trials to detect Trp53 mutations in the liver tumour failed (data not shown). Even the T-cell Based on the data presented in the IARC website and described in the legend of Figure 3 . Functional assays are predicted as impacts of mutations in yeast assays and structural computation. Count is the number of the entries in the database.
Hepatic cancer by AID in mice A Takai et al lymphomas that developed in the earlier AID transgenic mice did not harbour Trp53 mutations (Kotani et al., 2005) . Therefore, the TNAP-AID mouse model is the first model in which Trp53 mutations can be detected unequivocally in non-cancerous tissues as well as in cancerous tissues that express AID. In spite of these differences, the two independent AID transgenic mice lines commonly developed liver tumours, making it unlikely that liver tumours in TNAP-AID mice are ascribed to unexpected variables such as the transgene integration sites and the segregation of relevant loci upon crossing of mice with different genetic backgrounds. However, the possibility that these variables somewhat modified the tumour frequency cannot be excluded. The overlap of mutational hot spots between TNAP-AID and human HCC (Table 3 and Figure 3b ) suggests that these mutations induced by AID have critical roles. The lack of Trp53 mutations in the earlier transgenic mouse model may reflect a different evolutionary path from the initiation to progression of liver tumours between the two models despite the common involvement of AID. This difference may be related to the difference in the frequency and aggressiveness of lymphomas between TNAP-AID and the earlier AID transgenic mouse, as discussed below. The point mutations observed in Trp53 are likely to be a direct effect of AID activity, because they share some molecular footprints with SHM of the immunoglobulin genes, including GC bias, frequent C-to-T transitions and transcription dependence. However, there was no correlation between the distributions of mutations and SHM hot spot motifs or DNA secondary structures in the Trp53 sequence. As these parameters show only weak association even for SHM, the small numbers of point mutations observed in this study may not be sufficient to achieve statistical significance. On the other hand, single-base insertions causing frameshifts in Trp53 were frequently observed in HCC but not in the noncancerous liver of TNAP-AID mice. As single-base insertions are relatively rare in SHM induced by AID, these might be caused by genetic instability (for example, impaired mismatch repair) acquired during the progression of the tumours.
The presence of mutations in non-cancerous tissue expressing AID is reminiscent of a study on human patients with chronic hepatitis (Kou et al., 2006) , together suggesting a causal role of AID in tumorigenesis. It is noteworthy that the mutations corresponding to two mutational hot spots in TP53 gene encoding human p53 (R273 and R175) were included in mutations found in TNAP-AID HCC. Other mutations were mapped close to the human hot spots (M246 and R267) (Figure 3b and Table 3 ). Among them three patterns of amino acid replacement, C40S, R264W and R270G, were observed repeatedly in multiple individuals. Such repeated appearance of the specific mutations in different individuals may indicate their significance in tumorigenesis. In addition to these common mutations, HCC and the non-cancerous liver contained quite diverse mutation patterns, which parallels heterogeneity of TP53 mutations within human HCC occurred in a single individual and is consistent with the 'field cancerization' model (Thorgeirsson and Grisham, 2002) .
The utility of the TNAP-AID mouse as a human HCC model depends partly on the lack of lethal lymphomas that were observed in almost all AID transgenic mice in our earlier study. To examine the reason why lymphomas were infrequent and less aggressive in the TNAP-AID model, mutations caused by AID and its expression in T lymphocytes of TNAP-AID mice were analysed by sequencing the Trp53 coding sequence (Table 2 ) and flow cytometry (Supplementary Figure 4 ). From these analyses, it was found that Trp53 was not mutated, but AID was expressed in the thymocytes of the TNAP-AID mice. The level of AID expression in the thymus of TNAP-AID mice was half than that seen in the earlier AID transgenic line in a qRT-PCR analysis (data not shown). We speculate that the difference in the levels of AID expression in T cells may be one of the reasons for this, although the difference in the genetic background (C57BL/6:129/Sv hybrid versus pure C57BL/6) cannot be excluded.
The TNAP-AID mice did not develop germ cell tumours despite the expression of AID in the testes (Figure 4d ) and the absence of GFP in the seminiferous tubules and oocytes of the ovaries (data not shown). We reported earlier the lack of lymphomagenesis in B-cellspecific AID transgenic mice obtained by crossing the same AID cTg line with CD19-Cre mice (Muto et al., 2006) , suggesting that some protective mechanism might exist in B cells, which have physiological expression of AID. A similar reason might apply to germ cells because AID has been reported to be expressed physiologically in the human testis (Schreck et al., 2006) and mouse ovary (Morgan et al., 2004) .
To conclude, we generated a new line of AID transgenic mice that develop HCC but not lethal T-cell lymphoma. We consider that the TNAP-AID mouse model is useful for human HCC studies because it has been shown that AID is induced in the human pre-cancerous conditions of chronic hepatitis and cirrhosis (Kou et al., 2006) . The relatively long latency before HCC development in this model is reasonable, considering that it is a physiological recapitulation of a human tumour phenotype that takes decades to develop.
Materials and methods

Mice
The AID cTg mice (line 20) on a C57BL/6 background (Muto et al., 2006) were self-crossed to obtain homozygous transgenic mice, which were maintained in a specific pathogen-free facility at the Kyoto University Faculty of Medicine and Shiga Medical Center. This mouse line has been deposited at the Riken Bioresource Center (Tsukuba, Japan; No. RBRC00892). The TNAP-Cre mice (Lomeli et al., 2000) were gifted by Dr Andras Nagy (Mount Sinai Hospital, Toronto, Canada) and maintained by self-crossing between the heterozygous mice. C57BL/6 mice were purchased from Shimizu Laboratory Supplies Co., Ltd (Kyoto, Japan). All mice were fed ad libitum and were killed by cervical dislocation for censoring, or observed until spontaneous death. Upon censoring and spontaneous death, the numbers of macroscopic tumours were counted after laparotomy and thoracotomy. Kaplan-Meier survival curves were analysed using Prism 4.0 software (Graphpad, San Diego, CA, USA). All animal experiments were approved by the Ethical Committee for Animal Experiments and performed under the Guidelines for Animal Experiments of Kyoto University and Shiga Medical Center.
Histology and immunohistochemistry
Paraffin-embedded mouse organs were sectioned and stained with haematoxylin and eosin. a-Fetoprotein was detected using anti-a-fetoprotein antibody (Dako, Glostrup, Denmark) and an ABC kit (Vector, Burlingame, CA, USA) for paraffinembedded sections of formalin-fixed liver. For AID immunostaining, freshly isolated liver was fixed in 4% paraformaldehyde in phosphate-buffered saline on ice for 2 h and immersed in 30% sucrose for 18 h. After embedding in OCT compound (Sakura Fineteck Japan, Tokyo, Japan) in liquid nitrogen, 8-mm sections were sliced and mounted on glass slides. Hoechst 33342 dye was used to visualize nuclei. AID protein was detected using the monoclonal anti-AID antibody, MAID-2 (Tsuji et al., 2008) , with peroxidase-labelled donkey F(ab 0 )2 anti-rat IgG (Jackson ImmunoResearch, West Grove, PA, USA) and signal amplification using TSA Plus DNP and TSA Plus TMR kits (Perkin Elmer, Waltham, MA, USA). Images taken with a fluorescence microscope (DM5000B; Leica, Wetzlar, Germany) were merged using Photoshop (Adobe, San Jose, CA, USA).
Mutation analysis
Cancerous and non-cancerous liver tissues of approximate volume of 50 mm 3 were macroscopically dissected, frozen in liquid nitrogen and powdered with a frozen-cell crusher (Cryopress; Microtec, Funabashi, Japan). Genomic DNA and total RNA were extracted using the QIAamp DNA Mini kit (Qiagen, Duesseldorf, Germany) and the QuickGene kit (Fuji, Tokyo, Japan) from liquid nitrogen-frozen tissues that had been dissected macroscopically from non-cancerous livers and cancerous nodules. Sequencing of Trp53 was performed as described earlier (Matsumoto et al., 2007) except for primers for the non-transcribed regions, sequences of which are shown in Supplementary Figure 5 . Mutations of the Myc, Pten and Cdkn2a genes were analysed as described (Matsumoto et al., 2007) except for primers, sequences of which are shown in Supplementary Figure 5 . Statistical significance was assessed by Fisher's exact test using Stata 8.2 software (Stata Corp, College Station, TX, USA). Searching for SHM hot spot motifs and DNA secondary structure analyses were performed using GENETYX-MAC 14 (Genetyx Corp., Tokyo, Japan) and mfold software (Zuker, 2003) , respectively.
qRT-PCR cDNA was synthesized using the iScript kit (Bio-Rad, Hercules, CA, USA). Quantitative PCR (qPCR) was performed using QuantiTect reagent (Qiagen) and a real-time thermal cycler (Mx3000P; Stratagene, La Jolla, CA, USA). Oligonucleotide sequences are shown in Supplementary Figure 5 .
Western blotting
Mouse organs were dissected, frozen in liquid nitrogen and powdered with a frozen-cell crusher (Cryo-press). Proteins were extracted from the tissue powder using 10 mM sodium phosphate (pH 6.8), 200 mM NaCl, 1.5 mM MgCl 2 and 0.2 mM EDTA with a protease inhibitor cocktail (Complete; Roche Diagnostics, Mannheim, Germany). Protein of 100 mg per lane was applied to a 5-20% polyacrylamide gel (Bio-Rad), electrophoresed and blotted on to Hybond P membrane (GE Healthcare, Buckinghamshire, UK). Signals were generated using peroxidase-labelled anti-rat IgG (Jackson ImmunoResearch) and the ECL Plus system (GE Healthcare) and detected with a LAS-3000 mini image analysis system (Fuji).
